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Abstract 
 
A major factor in the success of Staphylococcus aureus as a pathogen is its vast arsenal 
of virulence determinants and, more importantly, the tight and precisely- timed 
regulation of these factors. Here we investigate the product of the S. aureus gene, 
SAUSA300_1984, encoding a putative transmembrane protein. This as yet 
uncharacterized protein belongs to the Abi (abortive infection) family, which are 
commonly annotated as CAAX-proteases, and are significantly understudied in 
prokaryotes. In S. aureus the disruption of SAUSA300_1984 results in a drastic 
reduction of proteolytic and hemolytic activity, as well as diminished pigmentation. This 
phenotype appears to be mediated through reduced agr expression, as determined by 
qPCR analysis. Importantly, known regulators of agr, such as CodY, MgrA, and ArlR, 
demonstrate no significant changes in transcription upon 1984 disruption, whilst major 
alterations were observed for downstream effectors of agr, such as sarS, RNAIII, rot 
and hla. Complementation and site-directed mutagenesis of 1984 demonstrated that 
proteolytic activity (via conserved EE residues) was not required for this phenotype, 
suggesting a potential protein-protein interaction mechanism of interaction. Proteome 
analysis of the 1984 mutant confirmed a number of our transcriptional observations, 
such as an increased abundance of Rot and surface associated proteins, as well as a 
marked decrease in Agr-system proteins levels, with the most striking being AgrB. 
Virulence profiling revealed a decreased ability of the 1984 mutant to evade 
 vii 
constituents of the innate immune response, and impaired survival during murine 
models of infection. Given that SAUSA300_1984 is encoded 3 genes downstream of 
RNAIII, our current working hypothesis is that this Abi protein functions to control agr 
activity through communication with membrane components of this system, potentially 
via interaction with AgrB. Confirming this, and determining the upstream effectors of 
this regulatory system are studies currently ongoing in our laboratory. 
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Chapter One: Introduction 
 
Staphylococcus aureus 
S. aureus is a non-motile, non- spore forming, gram-positive opportunistic pathogen. It 
is a facultative anaerobe, and belongs to the phylum of Firmicutes. Firmicutes are 
defined by their relatively low guanine and cytosine content in DNA [1]. S. aureus is 
comprised of approximately 33% G+C chromosomal content, and has a genome of 
approximately 2.8 million base pairs [2]. Staphylococcal disease was first clinically 
observed in the early 1880s by Scottish surgeon Alexander Ogston. Ogston described 
the bacteria’s role in disease, and more specifically abscess formation and sepsis [3]. 
Following the examination of pus from a knee joint abscess, he described the presence 
of masses that looked like grape bunches; this observation led to the naming of the 
bacteria [4]. The etymology behind Staphylococcus is Greek, from the words staphyle, 
meaning ‘bunch of grapes,’ and kokkos, meaning ‘berry.’ [4]. Following the 
aforementioned discovery of the staphylococcal genus, a German physician, Friedrich 
Julius Rosenbach, observed golden colony pigmentation in a staphylococcal strain. The 
Latin term for ‘gold’ is aurum, thus, Rosenbach established the binomial nomenclature, 
Staphylococcus aureus, in 1884. [4]. The observed golden pigmentation in S. aureus is 
a result of a carotenoid, staphyloxanthin [5]. This membrane bound carotenoid holds 
antioxidant properties, and is able to protect the bacterial cell from reactive oxygen 
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species, and consequently increase virulence [6]. S. aureus  can be further identified by 
a multitude of biochemical properties, such as the capability of fully lysing red blood 
cells and ability to survive in higher salinity [7]. Additionally, this specific species can be 
differentiated from other Staphylococci based on its ability to clot human blood as a 
result of being coagulase positive [8]. 
 
Disease Manifestation in S. aureus 
Over 130 years after its discovery, S. aureus continues to be an important pathogen in 
human disease. S. aureus can be found as a commensal bacterium in approximate 30% 
of the human population’s nasal passages; however, under the right circumstances, it is 
capable of causing disease [9]. S. aureus carriers are at higher risk for infection, as well 
as Methicillin-resistant Staphylococcus aureus (MRSA) carriers which are estimated to 
comprise 2% of the population [9]. S. aureus capable of causing a large array of 
infections, which can vary from superficial infections to much more invasive forms that 
can lead to death. Skin and soft-tissue infections (SSTIs), are very commonly attributed 
to S. aureus, in addition to endocarditis, pneumonia, osteomyelitis, and sepsis [10]. 
Preferred areas of S. aureus colonization include mucosal membranes and the skin of 
humans. However, the bacterium is able to infiltrate the bloodstream, following trauma 
and exposure in these areas. Skin to skin contact between a healthy and infected or 
colonized individual is the leading mode of transmission for S. aureus infections [11]. 
Recently, the emergence of community-acquired methicillin-resistant Staphylococcus 
aureus (CA-MRSA) has lead to a major increase in SSTIs, and leads to difficulty 
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recovering due to resistance. Additionally, the success S. aureus demonstrates in biofilm 
formation makes it a large problem in colonization of indwelling medical devices, such 
as stents and pacemakers  
 
Treatment for S. aureus infections varies greatly amongst SSTIs, and the 
aforementioned invasive infections. Clinicians must be capable of distinguishing 
amongst SSTIs, and must able to discern when an infection is more complicated and 
will require a more aggressive approach [10]. If mistreated, superficial infections may 
progress, spread, and lead to bacteremia. Uncomplicated SSTIs are considered those 
that are not accompanied by signs of systemic infection, for example fever. These 
infections can be treated by drainage and oral antibiotic therapy [11].  
 
Antibiotic Resistance in S. aureus 
Since the initial development of antibiotics, bacteria have been quick to evolve and gain 
resistance; some bacteria however, such as S. aureus, have done so at concerning 
rates. Horizontal gene transfer plays a major role in the growth of antibiotic resistance 
in bacteria [12]. Penicillin was first discovered in 1928 by Alexander Fleming and was 
first used on a patient in the early 1940s. This antibiotic began to be noted as the 
“miracle drug,” after observing a significant drop in mortality from previously fatal 
infections, and consequently igniting the ‘era of antibiotics’ [9]. However, a few years 
later cases of resistance began to arise, and by the late 1960s, more than 80% of 
isolates from S. aureus infections were resistant to penicillin [13]. Similarly, a β-
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lactamase resistance drug, methicillin, was first introduced in 1959 in order to treat S. 
aureus infections, which had previously shown this resistance to penicillin [14]. By 
1961, cases of methicillin resistance in S. aureus, had emerged, and shortly could be 
found across the globe. From this point on, MRSA continued to grow as a problem as it 
gained resistance to new therapeutic initiatives attempts at treating infection, and it can 
now be considered an epidemic problem [13].  
 
Antibiotic resistance in S. aureus has been described to occur in four different waves 
following its emergence. The initial wave (wave 1) was initiated by the emergence of 
penicillin as a treatment and subsequent resistance, and extends to present day [9]. 
This wave continues to this day as more therapeutics are being introduced, followed by 
S. aureus acquiring resistance. Wave 2 occurred following the introduction of 
methicillin, and thus introducing this new resistant strain, containing mecI, a 
staphylococcal chromosome cassette [9]. The mid 1970s started wave 3, which 
introduced the emergence of new MRSA strains containing additional staphylococcal 
chromosomal cassettes, such as mecII and mecII, which contributed to the ongoing 
pandemic in healthcare settings [9]. Lastly, the mid 1990s marked the emergence of 
community-associated MRSA, and commenced wave 4; a decade later, Vancomycin-
resistance S. aureus (VRSA) was observed in clinical isolates. As decades have passed, 
the burden of antibiotic resistance in S. aureus has continued to rise as well. 
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Hospital Acquired MRSA and Community Acquired MRSA 
For many years, MRSA infections were initially linked to patients in healthcare settings 
(HA-MRSA), also noted as a nosocomial infection [15]. However, the emergence of 
community-acquired MRSA (CA-MRSA) in the 1990s has brought forth infections in 
otherwise healthy individuals, and consequently, MRSA has evolved from being an 
exclusively healthcare related illness, to a global problem [16, 17]. MRSA infections 
have demonstrated a prevalence rate of 80,000 cases per year in the United States, 
with a consequent mortality of approximately 11,000 [18]. In many isolates, CA-MRSA 
strains have demonstrated an overexpression of agr, leading to the production of even 
larger amount of virulence factors, and have therefore become characterized for their 
increase in virulence.  
 
Over 20 different genetic lineages of CA-MRSA have been reported worldwide, with five 
demonstrating predominance across the globe, of which include, USA400, USA300, 
South West Pacific clone, Taiwan clone, and a European clone [17]. USA300 has been 
isolated from every continent across the globe, and this can be considered a pandemic 
clone [19]. Most reports of CA-MRSA have demonstrated the involvement of the 
USA300 clone, and specifically in the United States it is the most prevalent, and most 
likely cause of a future epidemic [17].  In study, CA-MRSA strains have demonstrated 
higher involvement with SSTIs, while HA-MRSA strains have shown wide involvement in 
respiratory and urinary tract infection, which are both widely associated with healthcare 
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settings [20]. However CA-MRSA has the capacity of causing major and lethal 
infections, such as fatal brain abscess and bacteremia.  
 
Global Relevance of MRSA 
Outbreaks and epidemics of CA-MRSA have been observed across the globe, making S. 
aureus an important cause of human disease worldwide. Morbidity and mortality 
associated with MRSA continues to rise, and parallel, the financial burden on healthcare 
systems rises as well [21]. This is an especially pertinent issue when discussing 
countries across the globe with limited resources. In addition to the identified 
intercontinental presence of MRSA, clonal lineages are being identified in different 
geographic regions [21].  
 
The United States, alongside many important countries in the Americas, such as Brazil, 
are demonstrating a prevalence of HA-MRSA of 50% or higher [16]. In South America, 
majority of countries demonstrate a prevalence of over 50%, and the remaining 25-
50%. Additionally, Eastern and southeastern Asia demonstrate very high prevalence at 
50% or higher in very large countries such as Vietnam, Thailand, Japan, Taiwan, and 
South Korea [16]. Also, Pacific island countries such as Papua New Guinea, Philippines 
Indonesia and Australia demonstrate high prevalence ranging from 25-50% [16]. 
Interestingly, considering the high population rates observed in many countries of 
Africa, only a few demonstrate prevalence of 25-50%, for example South Africa, Egypt, 
and Algeria; however, many rates are unknown and are most likely a result of 
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underreporting [16]. European countries demonstrate a large distribution of prevalence, 
ranging from less than 1% in countries such as Iceland and Norway, to over 50% in 
Malta. Portugal, Greece, and Italy demonstrate intermediate rates; however they are at 
the upper limit of the 25-50% category. In contrast, Spain, Ireland and the UK are at 
the lower limit of the 25-50% range [16].  
 
Over the past decades, MRSA rates have continued to rise rapidly worldwide. Although 
MRSA has been mostly observed as an endemic problem in healthcare settings, the 
emergence of CA-MRSA along with its spread has made MRSA into a greater problem. It 
has altered global epidemiology by increasing prevalence rates in countries, which 
previously had low rates, and this is of dire concern to public health [16]. To make 
matters worse, this epidemiological change is accompanied by the aforementioned 
increase in antibiotic resistance. Combined, these two issues bring forth terrifying 
scenarios of epidemics and pandemics, where treatment would be complicated due to 
the variety in clones emerging worldwide, and their resistance to common antibiotic 
therapies.  
 
Virulence Factors in S. aureus 
Pathogenicity in S. aureus is very diverse and highly modulated, with various 
possibilities depending on surrounding environment and circumstances. The pathogen 
produces a wide array of extracellular and cell wall proteins at different stages of 
infection in order to optimize its existence and goals [22]. For example, when the 
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bacteria are in the early stages of colonization, they will produce different proteins in 
comparison to when they are in stages of dissemination; this coordination is facilitated 
by notable global regulators of gene expression in S. aureus [22]. During earlier phases 
of growth, such as the exponential growth phase, adhesive, tissue-binding proteins are 
actively synthesized, which play a role in colonization of the host [22]. In contrast, in 
post-exponential growth phase, these cell wall proteins are repressed, whilst 
extracellular toxins and enzymes are actively produced in order to facilitate invasion and 
dissemination through the bloodstream [22].  
 
Exotoxins are a very common and important tool in the large arsenal of virulence 
factors in S. aureus. These toxins play a role in fighting the cells involved in host 
immune response, for example, leukocidins, such as Panton-Valentine Leukocidin (PVL), 
are responsible for killing polymorphonuclear (PMN) leukocytes, such as neutrophils and 
mononuclear macrophages. These toxins are noted as pore-forming toxins, which lead 
to lysis of these eukaryotic cells [23]. The lysis of leukocytes leads to further tissue 
damage in the host, due to the leakage of ROS and other oxidizing agents, this holding 
an important role in SSTIs and necrotizing disease [23]. Additionally, the four 
hemolysins (α, β, γ, δ) are capable of lysing erythrocytes, additionally, some 
hemolysins, such as α-toxin contribute to the development of specific diseases such as 
skin infections and necrotizing pneumonia [24, 25]. Another toxin, involved in toxic 
shock syndrome (TSST-1), is capable of causing cellular destruction of endothelial cells, 
and is a major component in disease [26]. Enterotoxins play a leading in food-borne 
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disease involving S. aureus; Staphylococcal enterotoxins are the second most common 
cause of food-borne illnesses, which potentially lead to hospitalization [27, 28]. 
 
S. aureus has ten secreted proteolytic enzymes, also noted as extracellular proteases 
[29]. These 10 extracellular enzymes include 6 serine-like proteases (splABCDEF), 2 
cysteine proteases staphopain A and staphopain B, 1 V8 serine protease, of which the 
other six are homologs, and 1 metalloprotease, aureolysin [29]. These extracellular 
proteases are explained to play an important role in virulence, and more specifically in 
regulated attachment of bacteria within the host. Biofilms are communities of bacteria 
that are very well structured, and which play a major role in S. aureus infection, and 
more specifically are heavily observed in nosocomial infection [30]. In S. aureus 
extracellular proteases hold an important role in biofilm formation and dispersal from 
biofilms. Proteolytic enzymes are very important in the ability for S. aureus  to transition 
from adhesive motives that demonstrate increased attachment, such as in biofilms, to a 
disseminating phenotype in order to further spread infection [30]. For example, these 
extracellular proteases can cleave specific host proteins, such as fibrinogen and 
fibronectin, and ultimately allowing the bacteria to propagate and spread. These 
proteases are also capable of cleaving the heavy chains of immunoglobulins in human 
hosts, which can then deter opsonization and elongate bacterial survival within the host 
[29]. In addition to modifying host proteins, extracellular proteases also play an 
important role n the modification of self proteins. Notably, many surface proteins, such 
as protein A and clumping factor B are cleaved by extracellular proteins, SspA and Aur 
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respectively, in order to facilitate the aforementioned transition of phenotypes [29]. 
Along with their role in adhesion, extracellular proteases also play a role in modulating 
the abundance of virulence factors at any given time point. Aureolysin for example 
plays a role in the tempering of phenol soluble modulins and alpha-toxin [29].  
 
In addition, S. aureus has other important enzymes, such as hyalurinidase, coagulase, 
catalase, and fibrinolysin. Hyalurinidase has a role in tissue invasion, this enzyme 
hydrolyzes hyaluronic acid, which is a major constituent of the extracellular matrix 
(ECM) found amongst eukaryotic cells, notably endothelial cells [31]. Hyaluronic acid is 
a viscous substance, which can protect from pathogen invasion. Following its 
degradation tissue is exposed to bacterial infiltration and can lead to spread of disease. 
Coagulase aids in the conversion of soluble fibrinogen (Factor I) to insoluble fibrin 
(Factor IA), a more stable form which is involved in the clotting process in blood [32]. 
Lastly, catalase is an enzyme involved in the reduction of hydrogen peroxide, and 
ultimately aids in the survival of S. aureus from attacks involving oxidants [33]. 
 
Surface proteins play a crucial role in S. aureus virulence as well; many are also noted 
as microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) 
[22]. Some MSCRAMMs include protein A, clumping factor A, extracellular- fibrinogen 
binding protein, and fibronectin- binding protein [34]. These proteins play a very 
important role in evasion of the innate immune system and survival. For example, 
surface associated protein A is capable of binding host immunoglobulins in order to 
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prevent opsonization, and furthermore is capable of degrading the immunoglobulin 
[35]. Additionally, extracellular fibrinogen binding protein (Efb) plays a role in 
interfering with activation of the host complement response by binding directly to C3b, 
the activating binding protein [36]. Furthermore, clumping factor can blocks C3b which 
has already successfully bound to the bacterial cell, and by doing so prevent the further 
cascade brought forth by the complement system[37]. 
 
As previously noted, the golden color observed in S. aureus is a result of a carotenoid 
pigments found within the organism. This pigment is regulated by complex pathways of 
biosynthesis, which produce a wide variety of carotenoids.  Many carotenoids can be 
found in fruits and vegetables, such as carrots for example, that are known to be 
beneficial due to their antioxidant properties, and ability to reduce free-radical species 
[6]. Similarly, this pigmentation has shown to be a protective mechanism for S. aureus, 
which leads to the ability to evade oxidant-based elimination that is commonly observed 
as a mechanism in innate host immunity [6].  
 
Phagocytic leukocytes play a large role in the innate immune response of a host, and 
many of their mechanisms are a result of using reactive oxygen species (ROS) following 
phagocytosis of pathogen. In abundance, these molecules lead to pathogen death, 
however carotenoid presence and therefore pigmentation can act as a protective 
mechanism for the bacteria and can result in phagocyte survival [6]. Mutants that 
disrupt carotenogenesis have demonstrated impairment in survival following exposure 
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to neutrophils, increased sensitivity to oxidants, and decreased pathogenicity in vivo 
[6].  
 
The pigment found in S. aureus is termed staphyloxanthin; it is found to function as an 
antioxidant, and is reliant on a crt operon, which contains a SigB-dependent promoter 
[5]. Biosynthesis of staphyloxanthin is initiated by the condensation of two molecules, 
which together form dehydrosqualene; this reaction is catalyzed by CrtM, a 
dehydrosqualene synthase [5]. CrtN, a dehydrosqualene desaturase, forms the yellow 
intermediate, 4.4’ -diaponeurosporene, via dehydrogenation. The terminal methyl group 
of this intermediate is then oxidized by CrtP, a diaponeurosporene oxidase, resulting in 
4,4’- diaponeurosporenic acid [5]. Next, the glucose at the C1’’ position is esterified by 
CrtQ, a glycosyl transferase, and yields 4,4’-diapponeurosporenoate. Lastly, CrtO, an 
acyl transferase, esterifies the glucose on the C6’’ and yields staphyloxanthin [5].  
 
agr Quorum-Sensing System and Virulence Regulation 
The agr quorum sensing system is a global regulator of S. aureus virulence. The agr 
quorum sensing system is made up of two transcriptional units, RNAII and RNAIII. 
Each, transcript contains its respective promoter P2 and P3, respectively; RNAII is the 
agr operon, which is comprised of four genes (agrBDCA), upstream of RNAIII, a 
regulatory RNA [38].  As a quorum sensing system, regulation is dependent on cell 
density, which triggers a signal peptide to initiate autoregulation of the system [38].  
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The signal peptide in the agr system is noted as autoinducing peptide (AIP), and is a 
derivative of AgrD. AgrD is a polypeptide, which following proteolytic cleavage by AgrB, 
a multifunctional endopeptidase that also acts as a chaperone, results in the thiolactone 
AIP signaling peptide [39].  This signaling peptide in an optimal environment binds 
AgrC, the membrane sensor in a two-component regulatory system (TCS) [40]. Binding 
leads to cross-phosphorylation of AgrC and dimerization of the protein. AgrC then 
proceeds to phosphorylate AgrC, the cytoplasmic transcription factor (TF) response 
regulator in this TCS. Upon activation, AgrA directly binds the aforementioned P2 and 
P3 promoters, and accordingly upregulates the RNAII (agr) and RNAIII expression, as a 
positive feedback loop [38]. RNAIII subsequently acts on a large array of genes to 
modulate their expression, these genes are highly involved in virulence if S. aureus, 
thus explaining the crucial role of agr in S. aureus pathogenesis. 
 
In addition to the agr/RNAIII regulon, other regulators and transcription factors have 
an important role in virulence gene expression, and act in both agr-dependent and agr-
independent ways.  For example, SaeRS is another major TCS that is involved in global 
regulation of virulence gene expression [41]. Like many TCSs, SaeRS is widely affected 
by external stimuli, such as glucose, pH, and salt levels [42]. In this system, SaeS is the 
sensor for these environmental signals, and SaeR provides the response to these cues 
by upregulating specific virulence genes [18]. Additionally, the promoter for sae is also 
sensitive to signals resulting from exposure to phagocytes, such as increases in 
antimicrobial peptides or increases it ROS.  
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ArlSR is an additional TCS of S. aureus that holds a role in autolysis, and potentially a 
role in cell growth and division. Additionally, the arl system demonstrates involvement 
in the downregulation of certain virulence genes, such as coagulase and protein A [43]. 
The arl system is also able to downregulate RNAII transcription, leading to decreased 
expression of RNAIII and agr targeted genes during specific growth phases. Similarly, 
CodY is a global regulator in S. aureus, which is involved in metabolism, and is most 
expressed during nutrient excess [18]. CodY regulates over 200 genes, ranging from 
genes involved in metabolite biosynthesis to virulence, and more specifically agr. CodY 
has demonstrated involvement with the regulation of agr by preventing premature 
activation of the system during exponential growth phase [18]. 
 
The Sar protein family is comprised by another set of important global regulators in S. 
aureus. SarA is a DNA-binding protein that has a very important role in gene regulation, 
as well as agr expression. SarA is capable of directly binding the divergent agr 
promoters, P2 and P3, which consequently can lead to upregulation of the two 
transcriptional units [18]. SarA can also function independently from agr by directly 
binding promoters in many virulence associated genes [43]. Additionally, many of its 
homologues, such as SarT, SarX, and Rot have also been identified for their roles in 
virulence factor expression. SarT is an activator of SarS, which when expressed can 
lead to the upregulation of protein A and repression of α-toxin [44]. SarX has been 
shown as a negative regulator of agr, which can be activated by another homolog 
MgrA. Similarly, Rot represses toxin synthesis and upregulates surface attachment 
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protein expression, acting opposite of agr [44]. MgrA, another SarA homolog, has 
demonstrated its ability to upregulate about 175 genes and downregulate 180 [44]. 
MgrA is a DNA-binding protein, containing a helix-turn-helix (HTH) motif, observed in 
numerous Sar family proteins [45]. Mutations in MgrA have demonstrated an alteration 
in virulence factor production, for example, production of protein A and hemolysins 
[46].  
 
Alternative sigma factors, such as sigma factor B (SigB), demonstrate a role in the 
response to environmental stimuli, for example during waves of stress or energy 
depletion [42]. SigB has been shown to control the expression of numerous accessory 
genes, and has also displayed recognition of at least 23 different promoters of S. aureus 
genes. It has demonstrated involvement in modulation of aggregation by increasing the 
expression of adhesin proteins, such as clumping factor [43]. SigB has also proven to 
play a role in the pigmentation of S. aureus, leading to increased protection from 
oxidant and radiation. 
 
Abi-Domain Protein Family 
SAUSA300_1984 is a member of a large family of proteins, containing a conserved Abi 
(abortive infection) domain [47]. These proteins are majorly noted as CaaX amino 
terminal proteases involved in bacteriocin self- immunity; protease activity is implied by 
the role of Abi proteins in eukaryotes [48, 49]. Type II CaaX proteases are involved in 
post-translational modification in eukaryotic cells through a mechanism known as 
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prenylation, however this mechanisms has not been widely investigated in prokaryotes 
[48]. CaaX prenyl proteases in eukaryotes cleave the ‘aaX’ motif of a protein, followed 
by the addition of an isoprenoid on the remaining cysteine residue from the previous 
CaaX (C-cysteine, A- aliphatic amino acid, A- aliphatic amino acid, X- any amino acid) 
motif [47]. This CaaX protease family contains conserved amino acids across bacterial 
species and eukaryotes [47]. One of the conserved motifs is comprised of a two 
glutamic acids, and is noted as the putative catalytic site of the protein ‘EEXXXR’ [48].  
The other two conserved motifs include a phenylalanine and histidine ‘FXXXH,’ and an 
invariant histidine ‘H’ [48].  
 
In S. aureus, four other genes in addition to the previously stated have been identified 
to belong to this family of proteins, SAUSA300_2262 and SAUSA300_1724, demonstrate 
the conserved amino residues, whilst SAUSA300_0932 and SAUSA300_2405 don’t 
possess any conserved amino residues. Some of these have been investigated in a S. 
aureus Newman background, and have demonstrated a potential role in the trafficking 
of YSIRK/G-S signal peptides, or possible contributions to cell division [50]. In these 
studies, a SAUSA300_1984 homolog demonstrated a dissimilar role from the 
abovementioned, thus it did not follow the novel characterizations for altering cell 
surface proteins [50]. 
 
In a study investigating an Abi domain protein in Group B Streptococcus, it was 
demonstrated that the conserved proteolytic site does not play an essential role in the 
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proteins’ function, and rather the Abi protein interacted with a histidine kinase 
sensor/response regulator system, CovSR [51]. The Abi domain protein Abx1 was 
shown to be a regulator of the CovS histidine kinase sensor in GBS [47]. The 
demonstration that the Abi protein acts as a cellular regulator in GBS is a novel finding 
in bacterial studies [47]. Abi proteins in prokaryotes are becoming increasingly 
investigated, and novel findings continue to emerge, characterizing wide array of 
behaviors from prenylation, to cellular regulation, and roles in cell division.  
 
Project Aims 
The purpose of this study was to initiate the exploration of a previously uncharacterized 
protein. Following a previous screen for novel protease regulators, SAUSA300_1984 
demonstrated noteworthy changes in the bacteria’s phenotype. This change included a 
decrease in virulence determinant production, which implied a potential regulatory role 
of the 1984 protein. Due to the genes proximity to a global regulator of virulence, agr, 
the changes observed in a 1984 transposon mutant are of particular interest. In order 
to further characterize this gene and its protein product, transposon mutant strains will 
be utilized in transcriptional investigations to compare to wild-type, as well as virulence 
assays to determine the potential presence of attenuated virulence in ex vivo models. 
In addition, we want to investigate change in the 1984 mutant proteome in comparison 
to wild-type, and from here determine potential targets of this protein. In order to 
combat growing drug resistance, it is crucial that we begin developing therapeutics that 
“disarm” S. aureus, instead of solely killing and ultimately causing the development of 
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resistance in the pathogen. Further understanding of this uncharacterized protein can 
lead to a better understanding of S. aureus virulence mechanisms, which can then lead 
to novel developments in antimicrobial therapeutics.  
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Chapter Two: Materials and Methods 
 
Strains, Plasmids, and Primers 
All bacterial strains and plasmids utilized in this study are listed in Table 1. All primers 
used in cloning and qualitative real time- polymerase chain reaction (qRT-PCR) 
throughout this study are listed in Table 2. 
 
Media and Growth Conditions 
All media used in this study was prepared with deionized water, and steam autoclaved 
at 121°C for a minimum of 30 minutes. Bacterial strains were consistently grown at 
37°C shaking at 250 rpm. S. aureus bacterial strains were grown in tryptic soy broth 
(TSB) or tryptic soy agar (TSA), and E. coli bacterial strains lysogeny broth (LB) or LB 
agar. Some investigations required the use of antibiotics for selection; they were added 
in the following concentrations for S. aureus: Spectinomycin, Erythromycin, 
Tetracycline, and Chloramphenicol were all used at a concentration of 5 µg/ml, with the 
exemption of Lincomycin at a concentration of 25 µg/ml; some E. coli strains required 
ampicillin, which was used at a concentration of 100 µg/ml. Synchronization techniques 
were utilized in this study in order to obtain bacterial cultures at a specific growth 
phase.  In order to do so, overnight cultures were subcultured into fresh media using a 
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1:100 dilution factor. Some experiment required the standardization of bacterial 
cultures to an OD600 of 0.05.   
 
Table 1. Strains and Plasmids 
 
Organism Strain Marker 
E. coli DH5α N/A 
S. aureus RN4220 N/A 
S. aureus USA300 LAC WT N/A 
S. aureus USA300 LAC 1984::Tn E/L 
S. aureus USA300 LAC 1984::Tn::spc S 
S. aureus USA300 LAC 1984::Tn hla-lacZ:tet T 
S. aureus USA300 LAC 1984::Tn hla-lacZ:tet T 
S. aureus USA300 LAC aur-lacZ:tet T 
S. aureus USA300 LAC 1984::Tn aur-lacZ:tet T 
S. aureus USA300 LAC rot::tet T 
S. aureus USA300 LAC 1984::Tn rot::tet T 
S. aureus USA300 LAC 1984::Tn pSPC C 
S. aureus USA300 LAC 1984::Tn::spc S 
S. aureus USA300 LAC agr-lacZ:ery E/L 
S. aureus USA300 LAC 1984::Tn::spc agr-lacZ:ery E/L/S 
E. coli DH5α pJB67::1984::Tn::Spc Native Complement A 
E. coli DH5α pJB67::1984::Tn::Spc Native 6His Complement A 
E. coli DH5α pJB67::1984::Tn::Spc Non-Native Site Directed Mutant Complement A 
S. aureus RN4220 pJB67::1984::Tn::Spc Native Complement E/L 
S. aureus RN4220 pJB67::1984::Tn::Spc Native 6His Complement E/L 
S. aureus RN4220 pJB67::1984::Tn::Spc Non-Native Site Directed Mutant 
Complement 
E/L 
S. aureus USA300 LAC pJB67::1984::Tn::Spc Native Complement E/L/S 
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Table 1. (Continued) 
*List of bacterial strain and plasmids utilized throughout this study. Markers depict 
antibiotic selection: S- spectinomycin; T- tetracycline; C- chloramphenicol; E- 
erythromycin; L- lincomycin; A- ampicillin. Tn indicates the insertion of a transposon in 
the gene. 
 
 
Table 2. Primer Sequences 
Primer Sequence Description 
OL 2123 GAGTTGTTATCAATGGTCAC F sarA qPCR 
OL 2124 ACTGCTTTAACAACTTGTGG   R sarA qPCR 
OL 2495 AACAATCGGATTTAGTACAG F sarS qPCR 
OL 2496 GTAAGTATTACGCTCATCAA R sarS qPCR 
OL 2536 AGTTTGCCACGTATCTT F agrB qPCR 
OL 2537 TTAGCTAAGACCTGCATC R agrB qPCR 
OL 2538 TTAGTCCAAGGGAACTC F sarR qPCR 
OL 2539 CAAACGACAGTTGTTCA R sarR qPCR 
OL 2540 TTAAGGAAGGAGTGATTTC F hld qPCR 
OL 2541 GTTCACTGTGTCGATAAT R hld qPCR 
OL 3166 CGCGAACGAGAAATCATACAATG F sigB qPCR 
OL 3167 TCTCTGAAGTCGTGATACATGC R sigB qPCR 
OL 3612 GGTCCTTTATTAGCAGCATATGTATTCAG F 1984 Internal 
OL 3613 CTGAATACATATGCTGCTAATAAAGGACC R 1984 Internal 
OL 3777 ATGgaattcTTAGTGGTGGTGGTGGTGGTGTGGAATAAAAATGTGATATATAAAATTCGC R 1984 6His Tag 
 
Organism	 Strain	 Marker	
S. aureus USA300 LAC pJB67::1984::Tn::Spc Native 6His Complement E/L/S 
S. aureus USA300 LAC pJB67::1984::Tn::Spc Non-Native Site Directed Mutant Complement E/L/S 
Plasmid pSPC C, S 
Plasmid pJB67 A, E 
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Table 2. (Continued) 
 
Primer	 Sequence	 Description	
OL 4009 AAAGGCAATTTGCCAGATGC F ccpA qPCR 
OL 4010 AATTGCTTCTTCGTCGCTGATAC R ccpA qPCR 
OL 4011 CTAGGTGAATATGCTGCTACAG F codY qPCR 
OL 4012 CCATTGTAATAGCAGCTTTATCG R codY qPCR 
OL 4034 CAGCGAGATTGAAAGCGAATAC F rot qPCR 
OL 4045 CTGTCCATTTCTTTAAGCGTCATAG R rot qPCR 
OL 4036 GGCTCTATGAAAGCAGCAGATA F hla qPCR 
OL 4037 CTGTAGCGAAGTCTGGTGAAA R hla qPCR 
OL 4047 GCTCAAAGACAAGTTAATCGCTAC F mgrA qPCR 
OL 4048 CGTTTACAGGAGATTCATCCCA R mgrA qPCR 
OL 4049 CAAAGTTGCTGGGCTTGATTAC F arlR qPCR 
OL 4050 TTTGTGGCTGACGACGTAAA R arlR qPCR 
OL 4051 TTCGAACACGTGAAGAGAAAGA F sarZ qPCR 
OL 4052 CTGATGCTTCTCGTTCTGAAATG R sarZ qPCR 
OL 4053 CGGTAAAGAATTGAGGGATACATTACAT F sarV qPCR 
OL 4054 CTTGTCTTTCATCCGTTTCAGAAC R sarV qPCR 
OL 4055 CGATGAAGCATTGCAAAGATGA F sarX qPCR 
OL 4056 GTCCTACTTAAATCTAGCTCATCCA R sarX qPCR 
OL 4093 GGCAGATAATGATGATCGC F pJB67 MCS 
OL 4094 CATGTCAACGATAATACAAAATATAATAC R pJB67 MCS 
OL 4139 ATGcccgggATGACAAGATTATGGGCATCATTGC F 1984 External 
OL 4140 ATGgaattcCATGCTATTCTTATTTGTAAAGCGAAATAAAAA R 1984 External 
*List of primer sequences utilized in this study. Restriction sites are noted by underlined 
lowercase letters. Site-directed mutagenesis for SOE and his-tag addition is noted in 
bold.  
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Buffers  
PBS 
0.8% Sodium Chloride 
0.14% Disodium Phosphate 
0.02% Potassium Chloride 
0.02% Potassium Dihydrogen Phosphate 
Solution at a pH of 7.4 
 
Phage Buffer 
1M Magnesium Sulfate 
4mM Calcium Chloride 
50 mM Tris-HCl at a pH of 7.8 
5g/L of Sodium Chloride 
1g/L of Gelatin 
 
UDS Buffer 
6 M Urea 
50 mM Tris-HCl at a pH of 8 
5 mM DTT 
1% SDS 
 
TE Buffer 
10 mM Tris-HCl at a pH of 8 
1 mM EDTA 
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Bacterial Constructs 
Native Complement 
A native 1984 complement strain was created, in addition to a histidine tagged strain, 
due to the putative membrane location of the 1984 protein. In order to create the 
complement strain, OL 4139 containing a SmaI restriction site, and OL 4140 containing 
an EcoRI restriction site were used to amplify a fragment containing the 1984 gene via 
PCR. The resulting 1984 fragment was cloned into the multiple cloning site of pJB67, a 
plasmid with a CdCl2 inducible promoter. The constructs where then transformed into E. 
coli, and confirmed prior to transforming by electroporation into the S. aureus cloning 
strain RN4220. Following, a phage lysate was created using phi 11 bacteriophage 
(Φ11), this was subsequently transduced into the LAC USA300 1984 mutant strain for 
complementation, and subsequently confirmed via DNA sequencing. 
 
Non-Native Catalytic Site Mutant Complement 
Site directed mutagenesis was performed through the use of overlap extension PCR. In 
addition to the previously stated external primers, OL 4139 and OL 4140, internal 
primers containing a nucleotide mutation for the putative catalytic site, OL 3612 and OL 
3613 were also utilized. With the internal primers, two separate fragments were 
amplified containing a ‘GCA-GCA’ alteration from the original ‘GAA-GAA’, in order to 
substitute the double glutamic acid catalytic site in the protein, for an inactive double 
alanine site. PCR amplification using the external forward primer paired with the 
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internal reverse primer, in addition to the internal forward primer paired with the 
external reverse primer provided the two necessary fragments two create the site 
directed mutant complement of 1984. These two separate fragments were then 
amplified through PCR without any primers; this step allowed for the two fragments to 
anneal and create one whole fragment. Following the fragment was amplified once 
more through PCR, however this time the external primers OL 4139 and OL 4140 were 
included. This fragment was then cloned into the multiple cloning site of pJB67, a 
plasmid with a CdCl2 inducible promoter. Following plasmid cloning, the construct was 
transformed into E.coli, and positive colonies were confirmed by sequencing. Plasmid 
was then isolated and electroporation was used to transform into the S. aureus cloning 
strain, RN4220. Following, a phage lysate was made using Φ11 bacteriophage, and 
transduced into the LAC USA300 1984 mutant strain for complementation. The non-
native site directed mutant complement strain was confirmed via DNA sequencing. 
 
Native His-Tagged Complement 
Similarly to the native complement, a fragment was amplified with OL 4139 forward 
primer containing a SmaI restriction site, and OL 3777 containing a EcoRI restriction 
site and the respective nucleotide sequences encoding for histidine prior to the stop 
codon, which when translated results in a 6 histidine tag at the proteins C-terminus. 
The resulting 1984-His6 fragment was then cloned into the multiple cloning site of 
pJB67, a plasmid with a CdCl2 inducible promoter. The constructs where then 
transformed into E. coli, and confirmed prior to transforming by electroporation in S. 
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aureus cloning strain RN4220. A phage lysate was then made with Φ11 bacteriophage, 
and transduced into the LAC USA300 1984 mutant strain for complementation. Lastly, 
the his-tagged complement strain was confirmed via DNA sequencing.  
 
Transcriptional Assays 
Reporter Gene Fusions 
The hla-lacZ, aur-lacZ, and agr-lacZ fusions were all previously constructed using 
plasmid pAZ106. As a result, the only necessary steps were to create phage lysates 
from host strain using Φ11 bacteriophage, and transduce each phage lysate into both 
the wild-type and 1984 mutant strains. Following transduction, DNA was extracted from 
final bacterial strain containing the new fusion, and confirm via PCR. Once strains were 
confirmed, TSA plates containing X-gal substrate were used to observe transcript levels 
for the genes of interest.  
 
Quantitative Real Time-PCR 
mRNA was isolated from wild-type and the 1984 mutant cultures which had been 
synchronized to exponential growth phase. Cultures were synchronized in 5 ml volumes, 
to which 5 ml of cold sterile PBS was added. The cultures were then centrifuged at 
2,843 x g for 10 min, the supernatant was removed, and the remaining bacterial pellet 
was frozen overnight in the -80°C freezer. The bacterial pellets were resuspended in 
100 µl of TE buffer, and processed with glass beads in a Mini BeadBeater for 40 
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seconds. Following lysis, 700 µl of β-mercaptoethanol (BME) was added, followed by 
700 µl of RLT buffer. The samples were processed once more on the Mini BeadBeater 
for 40 seconds, followed by centrifugation at 17,000 x g for 2 seconds to burst bubbles. 
After centrifugation, 600 µl of the supernatant were collected into a new tube, and 900 
µl of 100% ethanol were added. Samples were then transferred to RNeasy spin 
columns, and treated with 350 µl of RWI buffer. The columns were then washed with 
500 µl of RPE buffer, and samples were eluted with 50 µl RNase-free water. Eluted 
samples were then treated with DNase enzyme at 37°C for 40 minutes. Using the 
iScript cDNA synthesis kit, cDNA was synthesized for the RNA samples, and PCR 
confirmed. Following, qRT-PCR was performed utilizing sybr green polymerase, and 20 
µl reactions. Reactions were performed in technical duplicates for each biological 
replicate; 16s rRNA was used as a control. Investigated genes included: rot, sigB, sarR, 
sarS, sarV, sarX, sarZ, agrB, hla, hld, sarA, codY, ccpA, arlR, and mgrA, respective 
primers are listed in table 2.  
 
Protein Assays 
Protein Extraction 
Following the growth of an overnight culture in biological triplicate, and subsequent 
synchronization to exponential growth phase, 1 ml of wild-type, 1984 mutant and agr 
mutant strain cultures were centrifuged, and the pellets resuspended in 300 µl of PBS. 
These samples were then treated with 10 µl of Lysostaphin at 37°C for 1 hour in a 
waterbath to allow lysis. Samples were then treated with 5 µl of DNAse I enzyme at 
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37°C for 1 hour in a waterbath. Samples were then centrifuged at 17,000 x g for 10 
minutes, at which point the supernatant was transferred into a new tube and labeled as 
the cytoplasmic fraction, and the pellet was resuspended in 100 µl of UDS buffer and 
labeled as the membrane fraction. Samples for the two fractions were then quantified 
for protein concentrations utilizing a Pierce 600 nm protein assay kit.   
 
Protein Digestion	
Proteins were treated with reducing buffer in order to induce denaturation. The samples 
were loaded on FASP spin columns, following the addition of 100 µl of Urea buffer, and 
centrifuged at 14,000 x g for 5 minutes. This wash step was repeated with 200 µl of 
Urea buffer, followed by the additional of 100 µl IAA buffer and light vortexing. The 
samples were then allowed to alkylate in the dark for 20 minutes, centrifuged at 14,000 
x g for 5 minutes, and removed of any flow through. Samples were then washed with 
100 µl Urea Buffer and centrifuged a total of three times. A total of, 100 µl of TEAB 
buffer was then added to the column, centrifuged at 14,000 x g for 5 minutes, and 
repeated 3 times. The filters were then transferred to new tubes and eluted. Trypsin 
was mixed into TEAB buffer at a 1:50 ratio, and added to the protein for digestion. 
Samples were incubated in a humidified 37°C incubator overnight. 
 
Desalt 
C18 MacroSpin columns were activated using 500 µl of 100% acetonitrile, followed by 
centrifugation at 1,100 x g for 2 minutes. Flow through was discarded, and the exterior 
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of the column was blotted dry. MacroSpin columns were then equilibrated by adding 
500 µl of 0.1% formic acid and centrifuging at the aforementioned speed and time, 
followed by the removal of flow through, for a total of 2 times. Following equilibration, 
the columns were ready for the addition of protein samples. Samples were added, 
centrifuged, and the flow through was removed from the collection tube. Samples were 
washed twice more with 0.1% formic acid, centrifuged, and removed of flow through in 
order to ensure salts and solvents were no longer present in the column. Once 
complete, the retained protein samples were eluted using 500 µl of 100% acetonitrile, 
and placed in a new, low-binding collection tube. Samples were then vacuum dried 
using SpeedVac centrifugation, and store at 4°C until ready for peptide quantification 
and MS analysis. 
 
Label-Free Mass Spectrometry 
Prior to analysis through mass spectrometry, proteins samples were digested, and 
peptides quantified with a Pierce 460 nm peptide assay kit. Samples were run on a 
hybrid linear ion trap (LTQ Orbitrap XL) mass spectrometer and protein informatics 
software (MaxQuant and Scaffold) was used. Protein intensities were averaged and 
compared to wild-type to determine fold changes in the mutant strains. Welch’s t test 
and a cut off of ≥ 1.5 change were used to determine statistical significance of proteins 
changes.  
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Virulence Assays 
Human Whole Blood Survival Assay 
Overnight bacterial cultures were grown in biological triplicate for wild-type, 1984 
complement, 1984 mutant, agr mutant, and the hla mutant strains. They were 
synchronized to exponential growth phase. Cultures were then washed three times in 
PBS, and standardized to an OD600 of 0.05 in PBS. The necessary volume was then 
calculated for each culture, and used to inoculate 1ml of whole human blood purchased 
from BioreclamationIVT. A sample was obtained at hour 0, and the blood cultures were 
then incubated at 37°C on a rotator for 4 hours. Samples were taken at hour 4, diluted 
to 10-6, and plated on TSA in technical duplicate to percent recovery from initial inocula. 
 
THP-1 Macrophage Infection Assay 
THP-1 human monocyte cells were acquired and properly seeded into a flask containing 
RPMI medium supplemented with L-glutamine, 10% fetal bovine serum, and 1% 
penicillin/streptomycin solution; cells were grown at 37°C in a 5% CO2 environment 
throughout. Once the cells reached a confluence of at least 80%, viable cells were 
counted using Trypan blue dye and a C-chip. Using the number of cells counted on the 
C-chip, a density was appointed, and a standard volume was used which contained 106 
cells per well, and these cells were spun down and resuspended in the aforementioned 
RPMI media, however also treated with 80 nM PMA (phorbol 12-myristate acetate) to 
induce differentiation and attachment. Six well plates were seeded with the treated 
cells, and the cells were incubated at 37°C in a 5% CO2 environment for 48 hours to 
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allow for differentiation and well adherence. Bacterial cultures were standardized to an 
OD600 of 0.05, and opsonized in 20% human sera at 37°C for 30 min. Differentiated 
macrophage cells were then washed with PBS, and infected with an MOI of 1 this was 
done with wild-type, 1984 mutant, and agr mutant strains in the aforementioned cell 
media sans antibiotic treatment. Plates were centrifuged at 450 x g for 10 minutes, and 
phagocytosis was allowed to proceed for 1 hour at 37°C in 5% CO2. Following bacterial 
uptake, cells were washed with PBS and treated with 30 µg/ml of gentamicin in FBS 
supplemented RPMI media for an additional hour at 37°C in 5% CO2 in order to kill 
remaining extracellular bacteria. To quantify bacterial cells phagocytosed, eukaryotic 
cells were washed with PBS, and treated with 1 ml of 0.5% Triton X-100 in order to 
cause lysis. Lysates were then diluted and plated on TSA in technical duplicates in order 
to determine the percent phagocytosed. In order to calculate intracellular survival, the 
experiment was performed as abovementioned; however instead of lysing after 
treatment with 30 µg/ml gentamicin, cells were washed and treated with media 
containing 5 µg/ml gentamicin, and allowed to proceed for no more than 24 hours at 
37°C in a 5% CO2. Following this final incubation, cells were lysed as previously 
described, followed by lysate dilution and plating on TSA in technical duplicate. CFU/ml 
obtained from this process was then compared to the percent phagocytosed, and 
intracellular survival was concluded.   
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Chapter Three: Results 
 
Exploration and Phenotypic Identification of 1984 as a Virulence 
Determinant in Staphylococcus aureus 
SAUSA300_1984 became a gene interest following exploration of uncharacterized genes 
in the S. aureus genome. The specific gene was located 3.8 kb upstream of the well-
studied agr operon (Fig. 1). Upon further investigation, this gene was noted to encode 
a protein that belongs to an Abi-domain family, with a theoretical role that suggested a 
function that is understudied in prokaryotes. This family of proteins is majority 
comprised of CaaX proteases, which in eukaryotes are involved in a process known as 
prenylation. Prenylation is a form of post-translational modification, and these proteases 
are ultimately involved in the modification of proteins in order to facilitate cell 
membrane anchoring.  
 
To date, five genes in the S. aureus genome belonging to this Abi-domain family 
(PF02517) of CaaX proteases have been previously characterized in our lab. This study 
has been completed through the utilization of transposon mutants. Upon 
characterization, one of these five genes, SAUSA300_1984, demonstrated a pleiotropic 
effect following disruption of the gene by transposon insertion. Analysis on 5% sheep 
blood agar demonstrated a significant decrease of hemolytic activity in the 1984 mutant 
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when compared to the wild-type strain, indicating that disruption of the 1984 gene in 
the mutant leads to a decrease in hemolysin production (Fig. 2A). Additionally, analysis 
on casein agar revealed a similar trend. Examination of proteolytic activity in the 1984 
mutant demonstrated a reduced zone of clearing, indicating a decrease in protease 
production when compared to the wild-type strain (Fig. 2B). 
 
 
Figure 1. Close Proximity of SAUSA300_1984 to agr Operon Suggests 
Potential Regulatory Role. Through analysis of the S. aureus genome, 
SAUSA300_1984 was discovered to be an uncharacterized gene located upstream of the 
well-studied agr operon. Considering the major role agr has in the regulation of 
virulence determinant production, the investigation of this uncharacterized gene was of 
interest. The close proximity to this major regulatory operon suggests a potential role in 
virulence factor regulation. 
 
With consideration of these substantial changes in hemolysin and protease production, 
the 1984 mutant was examined for potential growth deficit. The 1984 mutant strain 
was grown overnight in TSB alongside the wild-type strain. Testing for statistical 
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significance demonstrated no change in growth potential between the wild-type and 
mutant strain (Fig.3). Observations suggested that the 1984 protein plays a role in S. 
aureus pathogenicity, through regulation of virulence determinant production.  
 
 
 
 
 
 
 
 
 
 
Figure 2. The 1984 Mutant Demonstrates an Altered Phenotype with Changes 
in Virulence Factor Production. A side by side comparison of LAC wild-type strain 
(right) and the LAC 1984 mutant strain (left). Bacterial strains were plated on sheep 
blood agar in order to observe changes in hemolysis (A), and casein nutrient agar to 
observe changes in proteolysis (B).   
 
Bioinformatic Analysis of 1984 as a Member of the Abi Protein Family 
Utilizing bioinformatics allowed for further study of the uncharacterized 
SAUSA300_1984 gene. Investigation of the Abi family led to the finding of a highly 
conserved ‘Glu-Glu’ motif, which has been identified as the putative catalytic site for this 
family of proteins (Fig. 4A). As previously mentioned, majority of the members in this 
Abi protein family function through a proteolytic mechanism. Thus, the next step was to 
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investigate the role of the conserved Glu-Glu motif in the function of the 1984 protein. 
Protein visualization sources depict five transmembrane helices, two cytoplasmic loops, 
and two smaller extracellular loops. The cytoplasmic loop nearest the C-terminus 
contains the two glutamic acids, which constitute the hypothetical catalytic site (Fig. 
4B).  
 
 
 
Figure 3. The 1984 Mutant Strain Displays No Deficit in Growth When 
Compared to the Wild-Type Strain. Wild-type, 1984 mutant, and agr mutant strains 
were grown to exponential phase, and separately inoculated into TSB with a starting 
OD of 0.05. This was performed in biological triplicate and technical duplicate, and 
optical densities were taken every 2 hours. A student’s T-test with Welch’s correction 
demonstrated no statistical significance between wild-type and the mutant strains. Error 
bars are shown in ± SEM. 
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Figure 4. Bioinformatic Analysis Demonstrates a Conserved Hypothetical 
Catalytic Site in the Abi Family of Proteins and Hypothetical Protein 
Topology. An HMM logo obtained through bioinformatics illustrates the highly 
conserved Glu-Glu residue in the Abi family of proteins, these residues comprise the 
putative catalytic site. The role of this catalytic site was investigated through the use of 
alanine scanning. The two glutamic acid residues were substituted by two alanine 
residues, as shown in the wild-type and mutant amino acid sequence (A). Cellular 
location of the Glu141 and Glu142 residues was emphasized with hypothetical protein 
topology obtained through bioinformatics (B).  
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Alanine scanning is a technique that allows for the substitution of amino residues of 
interest with a chemically inert, and significantly smaller amino acid, alanine. Through 
the use of site-directed mutagenesis and overlap extension PCR (OE-PCR), a non-native 
mutant complement was constructed by substituting the two glutamic acid residues 
encoded by ‘GCA-GCA’ in the catalytic site for two alanine residues encoded by ‘GAA-
GAA’ (Fig. 4A). Subsequent to confirmation by DNA sequencing, the non-native 1984 
site-directed mutant was tested for hemolytic activity on sheep blood agar, alongside 
the native complement constructs (Fig. 5 C-D), wild-type (Fig. 5E), and the 1984 
mutant (Fig. 5A) strains. Hemolytic activity was restored in the native complement 
constructs (Fig. 5C-D), as well as the non-native site-directed mutant complement (Fig. 
5B). 
 
Figure 5. Site-Directed Mutagenesis of the 1984 Catalytic Site Negates the 
Theoretical Role as a Protease. Following site-directed mutagenesis and 
complementation of the 1984 gene, it is determined that the protein encoded by 
SAUSA300_1984 is not functioning through a proteolytic mechanism. Hemolytic activity 
is demonstrated on sheep blood agar. The 1984 mutant (A) illustrates the 
aforementioned decrease in hemolysis, and the non-native site-directed mutant 
complement (B), native his-tagged complement (C), native complement (D), and wild-
type (E) strains demonstrate normal or restored hemolytic activity. 
            A       B       C       D        E 
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The restoration of this virulence factor in the site-directed mutant indicates that the 
catalytic site does not play a major role in 1984 protein function; 1984 does not 
function through a proteolytic mechanism, rather it functions via protein-protein 
interaction. 
 
Transcriptional Studies Given the Suggested Influence of 1984 on Virulence 
Determinant Production 
Following the observed changes in hemolysin and protease activity in the 1984 mutant, 
transcriptional analysis proceeded through the use of reporter gene fusions. Two genes 
of interest, hla (α-toxin) and aur (metalloprotease aureolysin) had been previously 
constructed in our lab in the form of lacZ fusions. Each fusion, hla-lacZ and aur-lacZ 
was transduced into the appropriate wild-type strain (USA300 LAC) and into the 1984 
mutant strain. In order to analyze transcription of α-toxin and the metalloprotease 
aureolysin, the bacterial strains containing the lacZ fusions were plated on TSA 
containing a colorless lactose analog, X-gal. Upon transcription of the lacZ gene, and 
ultimate translation of the protein the gene encodes for β-galactosidase, interaction 
with this colorless substrate results in the production of blue pigmentation in the 
bacteria. This is a result of a reaction in which the substrate, X-gal, undergoes 
hydrolysis facilitated by the active enzyme β-galactosidase. Upon hydrolysis and 
spontaneous oxidation, the substrate produces a blue insoluble product, 5-5’-dibromo-
4-4’-dichloro-indigo. This blue product allows for the qualitative visualization of 
transcription. By observing a difference in blue pigmentation, one can discern a 
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decrease or increase of transcription in the gene of interest. When comparing transcript 
levels of hla in the 1984 mutant, there is an evident decrease, which is suggested by 
the decrease in blue product (Fig. 6A). A similar trend is illustrated when comparing 
transcription of aur in the 1984 mutant (Fig. 6B). The changes that occur as a result of 
the mutation of 1984 can now be described to be occurring at a transcriptional level.  
 
Considering agr is a major regulator of these virulence determinants, the next step was 
to investigate potential changes in transcript level of agr in the 1984 mutant. Through 
the same technique, an agr-lacZ fusion was transduced into the wild-type and 1984 
mutant strains. These bacterial strains were plated on TSA containing the necessary 
substrate x-gal, and the production of blue pigment was observed. The 1984 mutant 
strain containing the agr-lacZ fusion demonstrated a drastic difference in the production 
of blue pigmentation, and therefore the transcription of agr. In comparison to normal 
production in the wild-type strain, the 1984 mutant seems to contain minimal to no blue 
pigmentation in the bacteria (Fig. 7). Thus, it was concluded that not only does 1984 
hold a role in the production of virulence factors, but it is modulating the transcription 
of agr. Interestingly, within the two sample fractions, multiple proteins were found in 
common between the 1984 mutant and the agr mutant. 
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Figure 6. Analysis with Reporter Fusions Demonstrates a Transcriptional 
Decrease of Two Known Virulence Factors in the 1984 Mutant. A side by side 
comparison of LAC wild-type strain (right of divider line) and the LAC 1984 mutant 
strain (left of divider line). Bacterial strains containing hla-lacZ (A) and aur-lacZ (B) 
reporter fusions were plated on TSA containing a colorless substrate X-gal (IUPAC: 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside). Presence of blue pigment is indicative 
of β-galactosidase enzymatic activity, which corresponds to transcription of the lacZ 
reporter gene within the fusion. 
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Figure 7. Analysis with a Reporter Fusion Demonstrates a Decrease in 
Transcription of agr in the 1984 Mutant. A comparison between Wild-type strain 
(Right of divider) and the 1984 mutant (Left of divider) containing an agr-lacZ reporter 
fusion. These reporter fusion strains were plated on TSA containing a colorless 
substrate X-gal (IUPAC: 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside). Presence 
of blue pigment is indicative of β-galactosidase enzymatic activity, which corresponds to 
transcription of the lacZ reporter gene within the fusion. 
 
Role of 1984 on Other Known Regulators and Effectors of Staphylococcus 
aureus 
To further investigate the role of 1984 as a modulator of transcription, (qRT-PCR) was 
conducted with an array of gene targets. qRT-PCR analysis was conducted for both 
wild-type and the 1984 mutant strains, in biological triplicates and technical duplicates. 
The 16s rRNA gene was utilized to normalize the raw data, and mutant values were 
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standardized to wild-type. To begin this exploration, transcription of agrB, RNAIII, and 
hla were quantitatively analyzed. A highly significant decrease was noted for the three 
genes (Fig. 8A) Transcriptional levels of agrB demonstrated a 13.8-fold decrease in the 
1984 mutant. Additionally, as demonstrated with the use of an hla-lacZ fusion in the 
1984 mutant, qRT-PCR determined 14.8- fold decrease in the transcriptional level of hla 
in the mutant strain. The most profound change in transcription was noted in the 
transcript levels of RNAIII, where a 201-fold decrease was observed in the 1984 
mutant. Transcription of RNAIII is directly regulated by agr activity. Thus, a decrease in 
agr activity, along with another very important transcriptional regulator, rot, elicits this 
severe decrease in transcript level. The acquisition of this data confirms the 
transcriptional changes in agr, in a further quantitative manner than the initial 
investigation with lacZ fusions.   
 
Following the validation of decreased agr transcription, multiple known regulators of agr 
were examined. Regulators arlR, mgrA, codY, and ccpA have been very well studied for 
their role in regulation of virulence factors and agr, thus their study assisted in 
determining whether agr is being modulated directly or indirectly by 1984. Upon 
analysis by qRT-PCR, these known regulators demonstrated no significant difference of 
transcript levels in the 1984 mutant (Fig. 8B).  
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Figure 8. Quantitative Real-Time PCR Analysis Including Known Regulators 
and Effectors of agr Demonstrates Noteworthy Alterations of Transcription 
Levels in the 1984 Mutant. Quantitative real-time PCR analysis was performed on 
numerous targets to determine transcriptional changes in known regulators and 
effectors of agr, in addition to agr itself. Illustrated is the transcriptional comparison 
between USA300 LAC wild-type and the 1984 mutant. The 16s rRNA gene was used to 
normalize the data, and wild-type values were used to standardize the date (2-ΔΔCt). All 
analysis was performed in biological triplicate and technical duplicate. A student’s T-test 
with Welch’s correction was used to determine statistical significance (n.s., p > 0.05; *, 
p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001), error bars are shown in ± 
SEM.  
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Some very notable changes in other effectors were also observed following qRT-PCR. 
Most notably one specific transcriptional regulator, rot, acts opposite of agr and 
demonstrated a significant change in the 1984 mutant. Under normal conditions, agr 
upregulates RNAIII transcription, and RNAIII negatively regulates rot (Fig. 9). In the 
1984 mutant, we see a reverse in transcript levels with agr and RNAIII showing a 
decrease in transcription, there is a significant increase in rot transcript levels (Fig. 8C), 
specifically a 4.6-fold increase. This change further indicates the direct effect of 1984 
has on agr, and reinforces the certainty of the role in virulence determinant production. 
Additionally, sarA, demonstrated a 2.4-fold decrease in transcription in the 1984 
mutant. Other notable SarA homologs were also investigated and displayed significant 
changes in transcript levels: sarR a 2.6-fold increase, sarS a 10.9-fold increase, sarV a 
4.9-fold increase, sarX a 2.2-fold increase, and sarZ a 6.4-fold increase. In addition, 
global regulator, sigB, illustrated a 2.33-fold increase in the 1984 mutant.  
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Figure 9. Putative Map Illustrating the Direct Interaction of 1984 on agr and 
Other Regulators of Virulence Determinants in S. aureus. Following 
transcriptional analysis of the 1984 mutant, a hypothetical map of interacting regulators 
and effectors was developed. 1984 is believed to directly interact with agr, ultimately 
resulting in a downstream effect on virulence factor production. 
 
Proteomic Approach to Determine the Role of 1984 on Protein Production 
Noting all of the significant changes seen in the 1984 mutant on a transcriptional level, 
it was essential to determine if these changes were also present in the proteome. Using 
a proteomic approach, a multitude of changes were noted in the production of proteins 
for the 1984 mutant in comparison to wild-type. Proteomic analysis of the cytoplasmic 
and membrane fractions was performed on the wild-type, 1984 mutant, and agr mutant 
strains. Upon analysis of the raw data, 392 total proteins were identified from the 
cytoplasmic fraction. Of these identified proteins, 255 proteins were found in common 
between the wild-type and the two mutant strains (Fig. 10A). More notably, out of 542 
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total proteins identified in the membrane fraction, 321 were identified to be common 
amongst the three strains (Fig. 10B). 
 
Figure 10. Comparison of Identified Proteins Following Proteomic Analysis of 
Wild-Type, 1984 Mutant, and agr Mutant Strains. Use of a Venn diagram 
illustrates a comparison of proteins identified through proteomic analysis. The 
cytoplasmic fraction (A) compares wild-type (Cyto _WT), 1984 (Cyto_1984), and agr 
(Cyto_Agr) mutant strains. Similarly, the membrane fraction (B) compares wild-type 
(Mem_WT), 1984 (Mem_1984), and agr  (Mem_Agr) mutant strains. The center 
highlighted in yellow represents common proteins that are found in all of the three 
strains. The cytoplasmic fraction illustrated 255 proteins out of 392 total that all three 
strains share in common (A). In the membrane fraction, 321 identified proteins out of 
542 total proteins are shared by all three strains (B). 
 
 
Many of the changes seen on a protein level were similar to the trends previously 
characterized in the qRT-PCR analysis.  Highly notable was the 15.6-fold increase in the 
aforementioned repressor of toxins, rot (Table 3), validating the transcriptional studies 
above. Changes in the production of Rot protein further imply the alteration of agr and 
RNAIII in the 1984 mutant. Another change that further endorses the initial change 
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displayed in transcript level is that of AgrB. Protein intensity values for AgrB 
demonstrated a 7.9-fold decrease in the 1984 mutant when referenced to wild-type 
values (Table 4). Additionally, a new alteration is seen in the production of AgrA 
protein, presenting a 2.7-fold decrease of protein intensity in the 1984 mutant (Table 
3). This decrease in AgrA and AgrB production suggests the absence of 1984 leads to 
an overall decrease in autoregulation within the agr quorum sensing system.   
 
Looking back at the qRT-PCR results from this study, the significant decrease in sarS 
can be recalled (Fig. 8C). This change is particularly noteworthy considering the 
increase in immunoglobulin G binding protein A (protein A) abundance in the 1984 
mutant; protein intensities demonstrated a 21.72-fold increase. Referencing back to 
Figure 9, it is understood that sarS is a positive regulator of protein A, and a repressor 
of α-toxin. Considering that sarS is an effector of agr, it was no surprise to observe this 
significant increase in protein A abundance 
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Table 3. Notable Cytoplasmic Protein Fold Change in the 1984 mutant 
 
Protein Function Fold Change 
HTH-type transcriptional 
regulator rot (Rot) 
Repressor of toxins; global 
regulator +16.59 
HTH-type transcriptional 
regulator (SarR) 
Regulatory protein which down-
regulates sarA expression +1.96 
Accessory gene regulator 
A (AgrA) 
Response regulator in quorum 
sensing signal transduction -2.67 
Transcriptional regulator 
(SarA) 
Transcriptional regulator; Global 
regulator of several virulence 
factors; Regulator of agr 
-1.92 
Methicillin resistance 
protein (FemA) 
Susceptibility towards beta-lactam 
antibiotics when inactive; formation 
of cell wall peptidoglycan 
-2.49 
*Interesting protein changes following proteomic analysis of the cytoplasmic fraction 
 
Influence of 1984 on Virulence in Staphylococcus aureus 
Considering the significant differences observed in the transcriptional and translational 
levels of numerous regulators of virulence, it was necessary to investigate the potential 
role of 1984 in S. aureus pathogenicity. The 1984 mutant, agr mutant, hla mutant, wild-
type, the 1984 complement strains were studied for their ability to survive and 
proliferate in whole human blood. Bacterial strains were grown to exponential phase in 
biological triplicate, standardized to an OD600 of 0.05, and were then separately 
inoculated into 1 ml of whole human blood. Blood cultures were incubated at 37°C and 
 49 
samples were extracted at specific time points through hour 4. Percent recovery was 
determined following comparison of CFU/ml following incubation to the initial inocula 
(Fig. 11). As expected, the agr mutant demonstrated a significant decrease in ability to 
recover in a host environment; agr mutant illustrated 7.8-fold decrease. Furthermore, 
the 1984 mutant illustrated an even more pronounced deficit in ability to recovery with 
a 14.8-fold decrease. Both the wild-type and hla mutant recovered at 100%, and the 
1984 complement demonstrated a 1.4-fold increase, indicating an increased ability to 
propagate in human blood (Fig. 11). 
 
Table 4. Notable Membrane Protein Fold Change in the 1984 Mutant 
Protein Function Fold Change 
Accessory gene regulator 
B (AgrB) 
Involved in the processing of AgrD 
propeptide -7.87 
Immunoglobulin G binding 
protein A (Spa) 
Upregulated by SarS; Promote 
biofilm formation +21.72 
Extracellular matrix-
binding protein (Ebh) 
Promotes bacterial attachment to 
soluble and insoluble forms of 
fibronectin 
-7.40 
Immunoglobulin-binding 
protein (Sbi) 
Interacts with both the adaptive 
and innate host immune response +16.15 
Oligopeptide permease, 
peptide-binding protein 
(opp-1A) 
Iron and heme acquisition; role in 
infection models +21.275 
*Interesting protein changes following proteomic analysis of the membrane fraction 
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Figure 11. Analysis of Bacterial Survival In Whole Human Blood 
Demonstrates Deficit in the 1984 Mutant. Bacterial strains were grown in 
biological triplicate to exponential growth phase. All strains were standardized to an 
OD600 of 0.05, and were separately inoculated into 1 ml of whole human blood. Samples 
were taken at specific time points and percent survival was calculated using CFU/ml and 
the initial inocula. A student’s t-test was used to determine statistical significance (n.s., 
p > 0.05; *, p < 0.05), error bars are shown in ± SEM.  
 
Following the display of decreased survival ability in a host environment, the 1984 
mutant was investigated for its ability to evade the human innate immune response. 
THP-1 human macrophage-like cells were used at a 1 x 108 cells/ml. The differentiated 
THP-1 cells were infected separately in biological triplicate with 106 CFU/ml of the wild-
type, 1984 mutant, and agr mutant strains. Cells were incubated at 37°C with 5% CO2 
supplement, and phagocytosis was allowed to proceed for one hour. The macrophage 
cells were then treated with gentamicin in order to eliminate remaining extracellular 
bacteria. To investigate intracellular bacterial content, the macrophage cells were lysed, 
the lysates were serially diluted, and plated on TSA. The percent of bacteria 
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phagocytosed was calculated by comparing CFU/ml at hour 1 to the initial inocula (Fig. 
12A). The 1984 mutant demonstrates a 1.8- fold increase in the percentage of bacteria 
phagocytosed; additionally, the agr mutant showed a 3.4- fold increase in phagocytosis. 
This increase in percent phagocytosed indicated that the 1984 mutant was less 
successful in evading the phagocytic cells. The agr mutant, as expected, demonstrated 
a much more pronounced increase in phagocytosed bacterial cells, and thus, a more 
significant decrease in ability to evade the phagocytic cells.  
 
To further investigate the ability to survive in a host immune environment, a further 24-
hour time point was examined to determine percent survival of the wild-type, 1984 
mutant, and agr mutant strains (Fig. 12B). Percent survival of the bacterial cells was 
determined by comparing the CFU/ml from hour 1, or phagocytosed cells, to the 
CFU/ml from hour 24. Upon analysis, the agr mutant demonstrated a 1.6-fold decrease 
in survival, whilst the 1984 mutant demonstrated a 1.5-fold decrease in survival. 
Overall, the mutant strains demonstrated a decreased ability to evade the host immune 
cells, in addition to a decreased ability to survive once inside the host cell. 
 
 
 
 
 
 
 52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. The 1984 Mutant Has Decreased Success in Evading Human Cells 
Involved in the Innate Immune Response. THP-1 Human Macrophage cells were 
separately infected by each bacterial strain in biological triplicate. Phagocytosis was 
allowed to proceed for 1 hour, at which time CFU/ml was compared to initial inocula in 
order to determine percent phagocytosed (A). The experiment continued to 24 hours, 
at which point final CFU/ml was compared to CFU/ml of hour 1, in order to determine 
percent survival within the cells. A student’s t-test was performed to determine 
statistical significance (*, p > 0.05), error bars are shown in ± SEM.  
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Chapter Four: Discussion 
 
S. aureus demonstrates an extraordinary ability to infect and survive within the host. 
This fascinating ability is a result of the pathogens’ large array of virulence factors, and 
their intricate regulation [43]. In particular, the agr quorum sensing system has been 
widely studied and is considered to be one of the most understood major regulatory 
systems in S. aureus virulence [18]. Importantly, complete genome sequencing, in 
addition to other resources such as ordered transposon libraries, have facilitated the 
identification of previously uncharacterized virulence affecting genes in S. aureus [2, 
52]. To this end, we present an exploration of the gene/protein 1984 in this work, 
revealing an apparent role in agr regulation.  
 
During our initial investigation of the 1984 transposon mutant, pronounced changes in 
two very prominent factors of S. aureus virulence, hemolysins and proteases 
demonstrated a very interesting alteration worth further investigating. Phenotypic 
characterization of the 1984 mutant demonstrated that the mutant’s ability to lyse 
blood cells and the ability to hydrolyze proteins is reduced due to decreased hemolytic 
and proteolytic activity, respectively. This pleiotropic effect following the disruption of 
1984 by a transposon is indeed notable, and, given the genomic location and close 
proximity to the agr operon, these findings provided ample motive for continued 
investigation.  
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Supplementary investigation of the changes occurring in the 1984 mutant indicates 
transcriptional effects on agr, along with α-toxin and metalloprotease aureolysin. 
Utilizing lacZ as a reporter gene, we were able to characterize α-toxin and 
metalloprotease aureolysin activity on a transcriptional level. By observing the 
production of blue pigmentation in the bacteria growth, which corresponds to β-
galactosidase enzymatic activity, we infer the transcript levels of the reporter gene, 
which in turn corresponds to the transcription of the hla, aur, and agr fusions. The 
decrease of blue pigment production in the 1984 hla-lacZ and 1984 aur-lacZ fusions 
indicates a significant decrease in transcription of α-toxin and metalloprotease 
aureolysin, respectively. Similarly, the 1984 agr-lacZ fusion demonstrates a much more 
dramatic decrease in blue pigmentation, indicating a reduction in transcript levels.  
 
Further analysis of transcript levels by qRT-PCR supports the results previously obtained 
by the lacZ reporter gene fusions. Quantification confirms a decrease of hla 
transcription in the 1984 mutant, validating the qualitative results from initial 
transcriptional studies. The first gene in the agr locus (agrBDCA), agrB, was 
investigated to further ascertain variations of agr activity between the 1984 mutant and 
wild-type. This quantification demonstrated a noteworthy decrease in transcript levels 
for agrB; and consequently, analysis of effector, RNAIII, reveals a substantial reduction 
of transcript levels in the 1984 mutant. The deviations observed in agrB and RNAIII 
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transcription may explain the diminution of virulence determinant production observed 
in the 1984 mutant strain [38].   
 
Observing the change in agrB transcription, and prior decrease in virulence factor 
production initiated the examination of well-known regulators in order to determine the 
possibility of an indirect regulatory effect by 1984. ArlR, the response regulator 
alongside ArlS is part of a two-component system, modulates the level of extracellular 
AIP, which leads to downregulation of the agr locus, and RNAIII transcription [43]. 
Similarly, global metabolic sensor and regulator CodY aids the downregulation of agr 
transcription under specific conditions [18, 38]. CcpA is another metabolite response 
regulator of S. aureus, which has demonstrated a role in the upregulation of RNA III, 
and thus virulence factors [18, 53]. Additionally, MgrA has been previously identified as 
a global regulator, demonstrating an effect on protein A, α-toxin, and numerous other 
virulence factors [46]. Examination of these known regulators using qRT-PCR illustrates 
no significant variation in transcript level, and therefore the changes seen in agr 
regulation, in addition to virulence factor synthesis, is not the consequence of an 
upstream effect resulting from alteration in these regulatory systems. 
 
Additional regulators and effectors were subsequently examined to further unravel the 
regulatory effect of 1984 on agr. The Sar family proteins have been widely studied for 
their roles in the regulation of agr and virulence factor production [44]. SarA itself is an 
activator of virulence genes and acts through agr dependent and independent 
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pathways. Analysis by qRT-PCR demonstrated a slight decrease in sarA transcription in 
the 1984 mutant. We conclude that this observed change does not account for the 
severe changes observed in agr and virulence determinant activity. Additional sarA 
homologs that were investigated on a transcriptional level include rot, sarR, sarS, sarV, 
sarX, and sarZ. With the exception of sarA, all other homologs in this study 
demonstrate a significant increase in transcript levels [44].  
  
One of the most notable differences is an increase in rot, which holds an important role 
in the upregulation of cell wall proteins, and downregulation of toxin production; an 
opposite role to agr [54]. rot is repressed by RNAIII under normal conditions; however 
in the 1984 mutant, a significant increase is observed. Therefore the increase in 
transcription of rot in the 1984 mutant further sustains the changes observed in agr 
upregulation, and consequent RNAIII regulation. SarS is an effector of SarT, a SarA 
homolog which under normal conditions is repressed by both sarA and agr [44]. 
Additionally, SarS is an activator of spa and repressor of hla. Given the observed 
decrease in both sarA and agr transcription in the 1984 mutant, an increase in SarT 
activity is expected, and consequently we observe a significant change in the increase 
of sarS transcription in the 1984 mutant.  
 
SarR is a DNA-binding protein that has been shown to repress SarA activity by binding 
one of the gene’s promoters [44]. In the 1984 mutant we observe a slight increase in 
transcription of sarR, which corresponds to the aforementioned decrease seen with 
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sarA. SarX, another homolog, is activated by mgrA, which demonstrated no change in 
transcript levels. Although no change is observed in mgrA, an increase is seen in sarX 
transcription in the 1984 mutant [46]. SarV and SarZ, were the other two SarA 
homologs characterized by qRT-PCR. Both sarV and sarZ have been minimally 
characterized, however in studies they have demonstrated a potential role in virulence, 
eliciting attenuation upon deletion [44]. In the 1984 mutant we see a significant 
increase in transcript levels for sarV and sarZ. Given their suggested roles in the 
positive regulation of virulence (i.e. hla upregulation) [44] their increase in the 1984  
mutant further implies the observed attenuation of virulence displayed is a result of agr 
deficit , thus further implying it is the result of a direct interaction with 1984.  
 
Many of the changes seen on a transcriptional level were also observed in the 
production of those specific proteins. Following proteomic analysis, numerous 
membrane and cytoplasmic proteins were detected to have significant changes in the 
1984 mutant. Notable proteins include Rot, SarR, AgrA, and SarA in the cytoplasmic 
fraction, and AgrB, Spa, Sbi and ClfA, in the membrane fraction [55]. The 
transcriptional changes in rot were also demonstrated on a protein level with changes 
that are statistically significant. Additionally, both SarR and SarA demonstrate similar 
trends observed following qRT-PCR, in which the proteins demonstrate a slight increase 
and decrease, respectively. The slight fold changes observed in SarA and SarR seem to 
correspond with each other, a similar relation seen in their transcriptional quantification. 
Noting this less than 2-fold change in SarA, suggests that although the protein is being 
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affected by the lack of 1984 in the mutant, it is not a result of a direct effect, rather is 
likely an indirect effect due to downregulation of the Agr quorum sensing system. 
Changes in AgrA are documented for the first time in this study following proteomic 
analysis. A negative fold changes observed indicate a decrease in the phosphorylation 
of AgrA response, which validates the decrease in agr transcription. Most importantly, 
we observe a significant negative fold change of AgrB, a membrane constituent of the 
Agr regulatory system involved in the secretion of AIP.  
 
A very important aspect of S. aureus, which leads to success in host colonization via 
adherence to the extracellular matrix, includes adhesin proteins, specifically those 
belonging to the MSCRAMM family [34]. A significant increase in adhesin proteins, such 
as protein A (Spa), Iron-regulated surface determinant protein A (isdA), and 
immunoglobulin-binding protein (Sbi), are observed in the 1984 mutant. These proteins 
are commonly cleaved by proteases in order to regulate their expression and facilitate 
detachment from the cell wall and into a soluble form [56]. Decreases in AIP levels 
result in a reduction of agr activity and consequently a decrease in levels of 
extracellular proteases, which are necessary for protein cleavage [57]. This increase in 
surface proteins can be explained by lowered agr activity in the 1984 mutant. This 
increase in surface adhesins can result in increased propensity for biofilm formation, in 
addition to an overall attenuation in detachment [30].  This can result in a deficit in the 
1984 mutant for dispersal and migration in order to iniitate colonization of new sites for 
infection [58]. 
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The global changes in the 1984 mutant may elicit attenuated virulence as suggested by 
the ex vivo investigation. Disruption of the 1984 gene leads to myriad alterations of 
virulence regulators, and consequently changes in virulence factor production.  The 
1984 mutant demonstrates a deficit in the ability to evade the innate immune response, 
and ultimately less success in survival within a host environment[6]. Whole human 
blood contains numerous constituents, which together play an important role in the 
immune response against bacterial infection, for example lymphocytes, phagocytic 
leukocytes, antibodies, and enzymes. Given the role of S. aureus septicemia as a 
leading cause of death in S. aureus diagnoses [13], an ex vivo model of sepsis was 
used to investigate survival. Following analysis, the 1984 mutant exhibits a deficit in 
ability to survive, while the complementation of the 1984 gene using a multi-copy 
plasmid demonstrates increased ability to survive and recover in the presence of whole 
blood components [59]. The 1984 mutant was also studied alongside an agr mutant, a 
non-hemolytic strain, which demonstrates similar defect in survival and recovery. This 
loss in ability to thrive within a host environment indicates that the decrease in 
regulators and virulence determinant production translates to lowered survival ex vivo. 
 
An additional macrophage infection model was utilized to investigate the host innate 
immune response and the pathogenic abilities of the 1984 mutant. Macrophages 
attempt to internalize the bacteria in order to eradicate them.  However S. aureus has 
numerous factors which facilitate evasion of the host cells in addition to survival and 
proliferation following phagocytosis [60]. Macrophages, in comparison to neutrophils, 
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are long-lived phagocytic cells; they are more likely to play a role in dissemination due 
to their migratory nature [60]. To examine survival, a human macrophage cell line was 
used, and an agr mutant was utilized as reference. The 1984 mutant demonstrates both 
a decrease in ability to evade phagocytosis by macrophages, and a decrease in ability to 
survive once internalized by the host cell; these results are similar to those observed in 
the agr mutant, although not as severe. This is explained by the decrease in agr and 
RNAIII activity in the 1984 mutant. Observed decreases in global regulators of virulence 
determinants, such as hemolysins and proteases, leads to attenuated virulence in the 
1984 mutant [61]. 
 
Proteomic analysis provided further insight into the potential mechanism in which 1984 
acts. Changes observed in the protein levels of AgrA and AgrB support the hypothesized 
interaction with 1984. Reduction of the cytoplasmic response regulator in the agr 
system initiates a decrease in activity due to reduced phosphorylation by the system 
sensor, AgrC. This decrease can be the result of decreased production and export of the 
necessary autoinducing peptide (AIP), which acts as the auto-activating signal of the 
quorum sensing system [62]. The major decrease in protein AgrB, denotes the 
aforementioned decrease in AIP levels; given that AgrB is involved in the processing 
and secretion of the AgrD peptide, its decrease results in a decrease of AIP, and thus 
abated autoregulation of the agr system [63]. Through a mechanism of protein-protein 
interaction, we believe that the 1984 membrane protein directly interacts with AgrB. 
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Thus, the absence of 1984 leads to alteration in the quorum sensing system, which 
ultimately leads to a diminution in the upregulation of RNAII and RNAIII transcripts.   
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Future Directions 
 
Following the aforementioned investigations of the 1984 mutant, we have unraveled 
information that has led us closer to the function of this protein, and have acquired 
evidence that this protein may in fact be a constituent of the membrane. However, in 
order to further elucidate the role of 1984, it is necessary to confirm protein localization 
and discern the mechanism behind this newly characterized protein. During the study of 
1984, a histidine-tagged native complement was also constructed utilizing the CdCl2 
inducible-plasmid. By being able to produce a protein with a 6His tag, it is possible to 
purify the tagged protein via an affinity ligand or detect location via anti-His antibodies. 
Examination of the secreted, cytoplasmic, and membrane fractions by western blot 
analysis will allow for the confirmation of protein location.  
 
To further investigate the mechanism behind 1984, transmembrane protein topology 
mapping through the use of a substituted cysteine accessibility method (SCAM ™) [64] 
will be performed. Bioinformatics illustrates the hypothetical topology for the 1984 
protein containing 5 transmembrane helices. Through modification of the amino acid 
sequences in 1984 by introducing cysteine residues to various locations on the protein, 
structural relationship of the transmembrane helices can be investigated [64]. 
Additionally, this technique can lead to differentiation of amino acid residues that are 
critical to protein function. 
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As we believe that 1984 functions by interacting with a membrane constituent in the 
agr system, AgrB, it is necessary to investigate prospective proteins with which it 
interacts. Understanding these interactions are crucial to understanding the biological 
processes in which 1984 is involved. Utilizing a bacterial two-hybrid system (BTH) will 
allow for the investigation of interaction between 1984 and AgrB, or other potential 
partners. This method follows a “bait” and “target” technique in which 1984 acts as the 
bait, and potential proteins of interaction are the targets [65]. Protein-protein 
interaction may be detected following the activation of a reporter gene, for example 
lacZ. A clone library for binding partner screening would us closer to deciphering the 
regulatory role of 1984 in a complex network [66]. Cross talk amongst regulatory 
systems is very common in S. aureus; as a result, it is necessary to elucidate the role of 
newly characterized 1984 in virulence gene regulation. 
 
Another point of exploration includes the mechanism behind 1984 activation. In addition 
to determining which proteins 1984 interacts with, it is also necessary to determine how 
1984 activity is modulated. For example, further investigation could determine whether 
1984 is activated as a result of ligand binding, transcription factor binding to DNA, or 
direct protein-protein interaction. Nevertheless, it is crucial to understand the regulation 
of 1984, in addition to its own novel regulatory roles. 
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Appendix 
 
Table A-1. Proteins identified in Proteomic Analysis of Cytoplasmic Fraction 
 
Protein ID Gene  Fold change 
Q2FEP3 30S ribosomal protein S19 (RpsS) 19.24 
A0A0H2XFX7 HTH-type transcriptional regulator rot (Rot) 16.59 
Q2FHV1 Iron-regulated surface determinant protein A (IsdA) 15.25 
A0A0H2XI52 Uncharacterized protein (1863) 9.435 
A0A0H2XJG9 Uncharacterized protein (1684) 5.585 
A0A0H2XJH7 Immunoglobulin G binding protein A (Spa) 4.808 
Q2FG58 50S ribosomal protein L20 (RplT) 4.227 
A0A0H2XGG6 ABC transporter, ATP-binding protein (1285) 3.662 
A0A0H2XHU1 Succinate dehydrogenase, flavoprotein subunit (SdhA) 3.323 
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Table A-1. (Continued) 
 
Protein ID	 Gene 	 Fold change	
A0A0H2XIK0 Peptide deformylase (Def) 2.464 
A0A0H2XH01 Signal recognition particle protein (Ffh) 1.959 
Q2FEQ1 50S ribosomal protein L5 (RplE) 1.941 
Q2FEN9 50S ribosomal protein L3 (RplC) 1.768 
Q2FDQ7 L-lactate dehydrogenase 2 (Ldh2) 1.717 
Q2FK29 L-lactate dehydrogenase 1 (Idh1) -1.360 
A0A0H2XEX6 Transcription termination/antitermination protein (NusA) -1.521 
Q2FG31 UPF0173 metal-dependent hydrolase (1653) -1.557 
Q2FI10 Phosphoribosylformylglycinamidine synthase subunit (PurQ) -1.599 
A0A0H2XGD7 ATP-dependent 6-phosphofructokinase (PfkA) -1.622 
Q2FJM8 Xanthine phosphoribosyltransferase (Xpt) -1.634 
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Table A-1. (Continued) 
 
Protein ID	 Gene 	 Fold change	
A0A0H2XIW4 Probable malate:quinone  xidoreductases (Mqo) -1.863 
Q2FFA2 Uncharacterized leukocidin-like protein 2 (LukA) -2.399 
Q2FEP9 50S ribosomal protein L14 (RplN) -2.437 
A0A0H2XIJ3 Autolysin (Atl) -3.000 
Q2FGA5 tRNA-specific 2-thiouridylase MnmA (MnmA) -3.199 
A0A0H2XF07 Putative zinc-binding dehydrogenase (2317) -3.208 
A0A0H2XG28 Ribosome-binding ATPase (YchF) -3.270 
A0A0H2XHB4 Ribose-phosphate pyrophosphokinase (Prs) -3.347 
A0A0H2XGH4 Amidohydrolase family protein (2517) -3.803 
A0A0H2XKC5 ABC transporter, ATP-binding protein (0630) -4.599 
A0A0H2XG16 Clumping factor A (ClfA) -4.737 
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Table A-1. (Continued) 
 
Protein ID	 Gene 	 Fold change	
A0A0H2XK08 Oxidoreductase, short chain dehydrogenase/reductase family (2275) -5.152 
A0A0H2XI39 Uncharacterized protein (AmaP) -6.056 
A0A0H2XGT6 Alkyl hydroperoxide reductase (AhpD) -9.383 
A0A0H2XH45 Putative lipoprotein (SaeP) -14.94 
A0A0H2XHF0 Carboxylic ester hydrolase (PnbA) -25.26 
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Table A-2. Proteins Identified in Proteomic Analysis of Membrane Fraction 
 
Protein ID Gene  Fold change 
A0A0H2XJH7 Immunoglobulin G binding protein A (Spa) 21.72 
A0A0H2XH66 Oligopeptide permease, peptide-binding protein (Opp-1A) 21.27 
Q2FE79 Immunoglobulin-binding protein (Sbi) 16.15 
A0A0H2XKN2 Uncharacterized protein (pUSA10004) 15.73 
A0A0H2XH62 D-lactate dehydrogenase (Ddh) 11.70 
Q2FJH7 N-acetylmuramoyl-L-alanine amidase (Sle1) 9.924 
A0A0H2XHT0 ABC transporter, ATP-binding protein (2453) 7.736 
A0A0H2XIY3 HAD-superfamily hydrolase, subfamily IA, variant 1 (0557) 6.051 
Q2FG29 Alanine dehydrogenase 2 (Ald2) 5.661 
A0A0H2XKF0 Pyrimidine nucleoside transport protein (NupC) 5.530 
A0A0H2XEB0 Iron compound ABC transporter, iron compound-binding protein (HtsA) 3.883 
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Table A-2. (Continued) 
 
Protein ID	 Gene 	 Fold change	
A0A0H2XHX1 Putative teichoic acid biosynthesis protein B (0247) 3.543 
A0A0H2XJW8 Putative pyridoxal phosphate-dependent acyltransferase (0535) 3.522 
A0A0H2XHW1 ABC transporter ATP-binding protein (0620) 3.207 
A0A0H2XFS4 Phosphoribosylamine—glycine ligase (PurD) 3.107 
A0A0H2XJ90 D-isomer specific 2-hydroxyacid dehydrogenase family protein (2496) 3.069 
Q2FGI6 Probable glycine dehydrogenase (decarboxylating) subunit 1 (GcvPA) 2.936 
Q2FDW8 PTS system glucoside-specific EIICBA component (GGlcB) 2.804 
A0A0H2XFM4 Glucokinase (Glk) 2.404 
Q2FEZ3 Pyrimidine-nucleoside phosphorylase (Pdp) 2.279 
Q2FI17 Probable quinol oxidase subunit 2 (GoxA) 2.072 
A0A0H2XGA6 L-lactate permease (2313) 2.021 
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Table A-2. (Continued) 
 
Protein ID	 Gene 	 Fold change	
Q2FDQ4 Fructose-bisphosphate aldolase class 1 (Fda) 1.874 
A0A0H2XGF3 Dihydroxyacetone kinase, DhaK subunit (0636) 1.809 
Q2FKC0 Phosphopentomutase (DeoB) 1.795 
A0A0H2XHC2 Glutamate dehydrogenase (GudB) 1.760 
Q2FDQ7 L-lactate dehydrogenase 2 (Idh2) 1.756 
A0A0H2XHQ4 Alkyl hydroperoxide reductase, subunit F (AhpF) 1.743 
A0A0H2XH50 1,4-dihydroxy-2-naphthoyl-CoA synthase (MenB) 1.564 
A0A0H2XEF6 Purine nucleoside phosphorylase DeoD-type (DeoD) 1.521 
Q2FJ87 Uncharacterized epimerase/dehydratase  (0538) 1.505 
A0A0H2XEI4 Transcription termination/antitermination protein (NusG) -1.508 
A0A0H2XG62 Uncharacterized protein (YfrA) -1.509 
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Table A-2. (Continued) 
 
Protein ID	 Gene 	 Fold change	
Q2FG61 Trigger factor (Tig) -1.614 
Q2FJA2 50S ribosomal protein L1 (RplA) -1.633 
Q2FH25 2-oxoglutarate dehydrogenase E1 component (OdhA) -1.668 
A0A0H2XHD3 Uncharacterized protein (1729) -1.685 
Q2FEP2 50S ribosomal protein L2 (RplB) -1.741 
A0A0H2XGA1 Dehydrogenase family protein (2251) -1.746 
Q2FHM2 Methionyl-tRNA formyltransferase (FmtA) -1.748 
Q2FJA1 50S ribosomal protein L10 (RplJ) -1.780 
A0A0H2XG28 Ribosome-binding ATPase (YchF) -1.860 
Q2FEV0 Alkaline shock protein 23 (Asp23) -1.863 
Q2FJC3 Lysine--tRNA ligase (LysS) -1.865 
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Table A-2. (Continued) 
 
Protein ID	 Gene 	 Fold change	
A0A0H2XHC7 50S ribosomal protein L29 (RpmC) -1.866 
A0A0H2XFU7 Aldehyde dehydrogenase (AldA2) -1.890 
A0A0H2XJG5 Uncharacterized protein (2473) -1.900 
A0A0H2XKD0 Phosphoribosylaminoimidazole carboxylase, catalytic subunit (PurE) -1.913 
Q2FF08 50S ribosomal protein L31 type B (RpmE2) -2.108 
Q2FF06 Putative aldehyde dehydrogenase (2076) -2.127 
Q2FEM9 Lipid II:glycine glycyltransferase (FemX) -2.134 
Q2FER6 50S ribosomal protein L17 (RplQ) -2.138 
A0A0H2XF85 UvrABC system protein A (UvrA) -2.181 
Q2FGD8 30S ribosomal protein S20 (RpsT) -2.183 
A0A0H2XHS5 Putative thioredoxin (0789) -2.234 
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Table A-2. (Continued) 
 
Protein ID	 Gene 	 Fold change	
Q2FH99 Catalase (KatA) -2.293 
A0A0H2XH45 Putative lipoprotein (0693) -2.399 
A0A0H2XFR7 Chaperone protein (ClpB) -2.469 
A0A0H2XHR8 Uncharacterized protein (Pfpl) -2.474 
A0A0H2XGF4 Sodium:dicarboxylate symporter family protein (0382) -2.505 
A0A0H2XII5 Phosphotransferase system, fructose-specific IIABC component (2576) -2.534 
A0A0H2XK77 Uncharacterized protein (SaeQ) -2.559 
Q2FK73 PTS system glucose-specific EIICBA component (PtsG) -2.571 
A0A0H2XFW6 Dihydroorotate dehydrogenase (quinone) (PyrD) -2.627 
Q2FEC8 Uncharacterized lipoprotein (2315) -2.700 
Q2FJP8 30S ribosomal protein S6 (RpsF) -2.709 
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Table A-2. (Continued) 
 
Protein ID	 Gene 	 Fold change	
A0A0H2XFG6 Uncharacterized protein (1698) -2.737 
A0A0H2XIS0 Uncharacterized protein (1230) -2.963 
A0A0H2XKH6 Universal stress protein family (0067) -3.045 
A0A0H2XI39 Uncharacterized protein (AmaP) -3.080 
Q2FGH0 Superoxide dismutase [Mn/Fe] 1 (SodA) -3.282 
A0A0H2XH82 Putative lipoprotein (0372) -3.316 
Q2FGZ4 Cell cycle protein GpsB (GpsB) -3.506 
Q2FIM4 Epimerase family protein (0753) -3.727 
A0A0H2XGC6 Lantibiotic epidermin immunity protein F (EpiF) -4.203 
Q2FDU6 Dehydrosqualene desaturase (CrtN) -4.391 
A0A0H2XGV7 Methicillin resistance protein (FemA) -4.885 
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Table A-2. (Continued) 
 
Protein ID	 Gene 	 Fold change	
Q2FKI2 Probable copper-transporting P-type ATPase B (CopB) -5.164 
A0A0H2XKC5 ABC transporter, ATP-binding protein (AbcA) -5.203 
Q2FG56 Translation initiation factor IF-3 (InfC) -5.245 
A0A0H2XEN6 Putative membrane protein (1864) -5.312 
Q2FK70 PTS system EIIBC component (0194) -5.354 
A0A0H2XHQ0 Putative transcriptional regulator (2259) -5.499 
A0A0H2XJG9 Uncharacterized protein (1684) -5.795 
Q2FEI5 Putative formate dehydrogenase (2258) -5.865 
A0A0H2XI99 ESAT-6 secretion system extracellular protein A (EsxA) -7.589 
A0A0H2XG16 Clumping factor A (ClfA) -7.919 
A0A0H2XK60 Uncharacterized protein (0664) -10.87 
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Table A-2. (Continued) 
 
Protein ID	 Gene 	 Fold change	
A0A0H2XGT6 Alkyl hydroperoxide reductase (AhpD) -13.40 
 
